TrialCompass™ TCL
Back to trials
Not yet recruitingPriority 4 · Lower priorityNCT07467317

BV-CHP Real-life and Biological Evidences in Patients With sALCL

ClinicalTrials.gov

Plain-language summary

This trial is testing brentuximab vedotin (an antibody-drug conjugate targeting CD30) combined with CHP chemotherapy for patients with anaplastic large cell lymphoma (ALCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

What is ALCL, ALK+?

Plain-language overview of ALCL, ALK+ plus all curated trials for this subtype.

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

BV-CHP Real-life and Biological Evidences in Patients With sALCL

NCT07467317

Status: Not yet recruiting | Priority: Lower

Plain-language summary

This trial is testing brentuximab vedotin (an antibody-drug conjugate targeting CD30) combined with CHP chemotherapy for patients with anaplastic large cell lymphoma (ALCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 100 patients

Primary endpoint: To evaluate the progression free survival (PFS)

Ages: 18 Years to —

Start date: 2026-05 | Est. completion: 2028-05

Locations

0 US sites · 19 total

Contact

Uffici Studi FIL | startup@filinf.it | +390131033153

Sponsor: Fondazione Italiana Linfomi - ETS (OTHER)

Tags

ALCL · Newly diagnosed · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07467317

Prepared using TrialCompass (trialcompass.com) on August 3, 2026. For informational purposes only. Always discuss with your healthcare team.